The Proteasome and Myeloma-Associated Bone Disease

Area of Science:

• Oncology
• Bone Biology
• Pharmacology

Background:

• Multiple myeloma (MM) is characterized by severe bone disease, leading to osteolytic lesions.
• Unbalanced bone remodeling, with suppressed osteoblast activity, drives MM bone pathology.
• The ubiquitin-proteasome pathway is crucial for regulating bone turnover.

Purpose of the Study:

• To review the effects of proteasome inhibitors (PIs) on bone remodeling.
• To focus on the impact of PIs in the context of multiple myeloma bone disease.
• To update evidence on PIs in managing cancer-induced bone disease.

Main Methods:

• Review of preclinical studies on proteasome inhibitors (PIs).
• Analysis of in vitro data on PIs' effects on osteoblast and osteocyte survival.
• Evaluation of clinical data from multiple myeloma patients treated with PIs.

Main Results:

• PIs stimulate osteoblast differentiation and bone regeneration.
• PIs protect osteoblasts and osteocytes from cancer-induced cell death via apoptosis and autophagy.
• Clinical data show PIs increase bone alkaline phosphatase, normalize bone turnover markers, and reduce skeletal events.

Conclusions:

• Proteasome inhibitors positively impact bone remodeling in multiple myeloma.
• PIs demonstrate therapeutic potential for both multiple myeloma bone disease and general cancer-induced bone disease.
• Bortezomib treatment in MM patients stimulates osteoblast formation and preserves osteocyte viability.